Results 131 to 140 of about 275,929 (307)

Antibody Engineering for Nuclear Imaging and Radioimmunotherapy. [PDF]

J Nucl Med, 2022
Rodriguez C, Delaney S, Sarrett SM, Keinänen OM, Zeglis BM.   +4 more
europepmc   +1 more source

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

Antibody targeted nanoparticles for imaging and therapy of cancer

, 2010
The central hypothesis for this thesis is that antibody-targeted superparamagnetic iron oxide nanoparticles (SPIONs) can be used for diagnosis and therapy of cancer.
Vigor, K.L.
core  

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

A Review of Protein-Based COVID-19 Vaccines: From Monovalent to Multivalent Formulations

Vaccines
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in the COVID-19 pandemic, has profoundly impacted global healthcare systems and the trajectory of economic advancement.
Gui Qian, Cuige Gao, Miaomiao Zhang, Yuanxin Chen, Liangzhi Xie   +4 more
doaj   +1 more source

Monte Carlo Thompson sampling-guided design for antibody engineering. [PDF]

MAbs, 2023
Kakuzaki T, Koga H, Takizawa S, Metsugi S, Shiraiwa H, Sampei Z, Yoshida K, Tsunoda H, Teramoto R.   +8 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

La ingeniería de fragmentos de anticuerpos: imitando y expandiendo el sistema inmune [PDF]

, 2010
Since genetic engineering of humanized murine monoclonal antibodies was fi rst demonstrated over two decades ago, antibody engineering technologies have evolved based upon an increasing understanding of the mechanisms involved in antibody generation in
Sinclair, M. (Michael), García-Quiroz, F. (Felipe)   +1 more
core  

Scissor–CIBERSORTx Deconvolution Reveals Functional Heterogeneity of CTAL/aTAL Cells and Associated Biomarkers in Renal Fibrosis

Current Issues in Molecular Biology
Renal fibrosis (RF) represents a major pathological outcome of chronic kidney disease, currently accompanied by extremely limited therapeutic strategies.
Hengping Wang, Yuan Zhang, Jiale Li, Ying Fu, Huiyan Wang   +4 more
doaj   +1 more source

Unlocking the potential of agonist antibodies for treating cancer using antibody engineering. [PDF]

Trends Mol Med, 2023
Jhajj HS, Lwo TS, Yao EL, Tessier PM.
europepmc   +1 more source